Classification of mitocans, anti-cancer drugs acting on mitochondria

Mitochondrion

Volumn 13, Issue 3, 2013, Pages 199-208

  Neuzil, Jiri ^a,b   Dong, Lan Feng ^a   Rohlena, Jakub ^b   Truksa, Jaroslav ^b   Ralph, Stephen J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

Author keywords

Anti cancer therapeutics; Classification; Mitocans; Selectivity

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; ANTINEOPLASTIC AGENT; BCL 2 HOMOLOGY 3 MIMETIC; BROMOPYRUVIC ACID; DEOXYGLUCOSE; HEXOKINASE; HEXOKINASE INHIBITOR; LIPOPHILIC CATION; METFORMIN; MITOCAN DERIVATIVE; MITOCHONDRIALLY TARGETED ALPHA TOCOPHEROL SUCCINATE; PROTEIN BCL 2; RHODAMINE 123; THIOL REDOX INHIBITOR; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; VOLTAGE DEPENDENT ANION CHANNEL TARGETING DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; COLORECTAL CANCER; DRUG CLASSIFICATION; DRUG TARGETING; HUMAN; MITOCHONDRIAL DESTABILIZATION; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL INNER MEMBRANE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL OUTER MEMBRANE; MITOCHONDRION; MOLECULAR DYNAMICS; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; ANIMAL; CHEMISTRY; CLASSIFICATION; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MITOCHONDRIA; MUTATION; NEOPLASMS;

EID: 84883814194     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2012.07.112     Document Type: Review

References (118)

1. Adam-Vizi V., Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci. 2006, 27:639-645.
2. Albayrak T., Scherhammer V., Schoenfeld N., Braziulis E., Mund T., Bauer M.K., Scheffler I.E., Grimm S. The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis induction. Mol. Biol. Cell 2003, 14:3082-3096.
3. Anderson S., Bankier A.T., Barrell B.G., de Bruijn M.H., Coulson A.R., Drouin J., Eperon I.C., Nierlich D.P., Roe B.A., Sanger F., Schreier P.H., Smith A.J., Staden R., Young I.G. Sequence and organization of the human mitochondrial genome. Nature 1981, 290:457-465.
4. Astuti D., Latif F., Dallol A., Dahia P.L., Douglas F., George E., Sköldberg F., Husebye E.S., Eng C., Maher E.R. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 2001, 69:49-54.
5. Baggetto L.G., Testa-Parussini R. Role of acetoin on the regulation of intermediate metabolism of Ehrlich ascites tumor mitochondria: its contribution to membrane cholesterol enrichment modifying passive proton permeability. Arch. Biochem. Biophys. 1990, 283:241-248.
6. Belzacq A.S., El Hamel C., Vieira H.L., Cohen I., Haouzi D., Metivier D., Marchetti P., Brenner C., Kroemer G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 2001, 20:7579-7587.
7. Ben Sahra I., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., Le Marchand-Brustel Y., Giorgetti-Peraldi S., Cormont M., Bertolotto C., Deckert M., Auberger P., Tanti J.F., Bost F. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010, 70:2465-2475.
8. Bernal S.D., Lampidis T.J., McIsaac R.M., Chen L.B. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science 1983, 222:169-172.
9. Biassutto L., Dong L.F., Neuzil J., Zoratti M. Mitochondrially targeted anti-cancer drugs. Mitochondrion 2010, 10:670-681.
10. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
11. Burnichon N., Brière J.J., Libé R., Vescovo L., Rivière J., Tissier F., Jouanno E., Jeunemaitre X., Bénit P., Tzagoloff A., Rustin P., Bertherat J., Favier J., Gimenez-Roqueplo A.P. SDHA is a tumor suppressor gene causing paraganglioma. Hum. Mol. Genet. 2010, 19:3011-3020.
12. Bustamante E., Morris H.P., Pedersen P.L. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J. Biol. Chem. 1981, 256:8699-8704.
13. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
14. Chen Z., Zhang H., Lu W., Huang P. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim. Biophys. Acta 2009, 1787:553-560.
15. Cuzick J., DeCensi A., Arun B., Brown P.H., Castiglione M., Dunn B., Forbes J.F., Glaus A., Howell A., von Minckwitz G., Vogel V., Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011, 12:496-503.
16. Dell'Antone P. Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent. Med. Chem. 2009, 5:491-496.
17. Don A.S., Kisker O., Dilda P., Donoghue N., Zhao X., Decollogne S., Creighton B., Flynn E., Folkman J., Hogg P.J. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003, 3:497-509.
18. Dong L.F., Swettenham E., Eliasson J., Wang X.F., Gold M., Medunic Y., Stantic M., Low P., Prochazka L., Witting P.K., Turanek J., Akporiaye E.T., Ralph S.J., Neuzil J. Vitamin E analogs inhibit angiogenesis by selective apoptosis induction in proliferating endothelial cells: the role of oxidative stress. Cancer Res. 2007, 67:11906-11913.
19. Dong L.F., Low P., Dyason J., Wang X.F., Prochazka L., Witting P.K., Freeman R., Swettenham E., Valis K., Liu J., Zobalova R., Turanek J., Spitz D.R., Domann F.E., Scheffler I.E., Ralph S.J., Neuzil J. α-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 2008, 27:4324-4335.
20. Dong L.F., Freeman R., Liu J., Zobalova R., Marin-Hernandez A., Stantic M., Rohlena J., Rodriguez-Enriquez S., Valis K., Butcher B., Goodwin J., Brunk U.T., Witting P.K., Moreno-Sanchez R., Scheffler I.E., Ralph S.J., Neuzil J. Suppression of tumour growth in vivo by the mitocan α-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res. 2009, 15:1593-1600.
21. Dong L.F., Jameson V.J.A., Tilly D., Cerny J., Mahdavian E., Marín-Hernández A., Hernández-Esquivel L., Rodríguez-Enríquez S., Stursa J., Witting P.K., Stantic B., Rohlena J., Truksa J., Kluckova K., Dyason J.C., Ledvina M., Salvatore B.A., Moreno-Sánchez R., Coster M.J., Ralph S.J., Smith R.A.J., Neuzil J. Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J. Biol. Chem. 2011, 286:3717-3728.
22. Dong L.F., Jameson V.J.A., Tilly D., Prochazka L., Rohlena J., Valis K., Truksa J., Zobalova R., Mahdavian E., Kluckova K., Stantic M., Stursa J., Wang X.F., Freeman R., Witting P.K., Norberg E., Goodwin J., Salvatore B.A., Novotna J., Turanek J., Ledvina M., Hozak P., Zhivotovsky B., Coster M.J., Ralph S.J., Smith R.A.J., Neuzil J. Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm of efficient anti-cancer therapy. Free Radic. Biol. Med. 2011, 50:1546-1555.
23. dos Santos G.A., Abreu Lima R.S., Pestana C.R., Lima A.S., Scheucher P.S., Thomé C.H., Gimenes-Teixeira H.L., Santana-Lemos B.A., Lucena-Araujo A.R., Rodrigues F.P., Nasr R., Uyemura S.A., Falcão R.P., de Thé H., Pandolfi P.P., Curti C., Rego E.M. (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia 2012, 26:451-460.
24. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., Bredesen D.E., Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 1999, 5:1032-1038.
25. Fantin V.R., Berardi M.J., Scorrano L., Korsmeyer S.J., Leder P. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2002, 2:29-42.
26. Fruehauf J.P., Meyskens F.L. Reactive oxygen species: a breath of life or death?. Clin. Cancer Res. 2007, 13:789-794.
27. Fulda S., Kroemer G. Mitochondria as therapeutic targets for the treatment of malignant disease. Antioxid. Redox Signal. 2011, 15:2937-2949.
28. Fulda S., Scaffidi C., Susin S.A., Krammer P.H., Kroemer G., Peter M.E., Debatin K.M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem. 1998, 273:33942-33948.
29. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
30. Galluzzi L., Morselli E., Kepp O., Vitale I., Rigoni A., Vacchelli E., Michaud M., Zischka H., Castedo M., Kroemer G. Mitochondrial gateways to cancer. Mol. Aspects Med. 2010, 31:1-20.
31. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., Hann C.L., McKeegan E.M., Litvinovich E., Hemken P.M., Dive C., Enschede S.H., Nolan C., Chiu Y.L., Busman T., Xiong H., Krivoshik A.P., Humerickhouse R., Shapiro G.I., Rudin C.M. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 2011, 29:909-916.
32. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
33. Gimenez-Roqueplo A.P., Favier J., Rustin P., Mourad J.J., Plouin P.F., Corvol P., Rötig A., Jeunemaitre X. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 2001, 69:1186-1197.
34. Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria as targets for chemotherapy. Apoptosis 2009, 14:624-640.
35. Gottlieb E., Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 2005, 5:857-866.
36. Hanahan D., Weinberg R.A. Hallmarks of cancer. Cell 2000, 100:57-70.
37. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
38. Hayden E.C. Cancer complexity slows quest for cure. Nature 2008, 455:158.
39. Higgins M.J., Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu. Rev. Med. 2011, 62:281-293.
40. Huang P., Feng L., Oldham E.A., Keating M.J., Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000, 407:390-395.
41. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
42. Johnson L.V., Walsh M.L., Chen L.B. Localization of mitochondria in living cells with rhodamine 123. Proc. Nat. Acad. Sci. U. S. A. 1980, 77:990-994.
43. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
44. Kadenbach B., Ramzan R., Wen L., Vogt S. New extension of the Mitchell Theory for oxidative phosphorylation in mitochondria of living organisms. Biochim. Biophys. Acta 2010, 1800:205-212.
45. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
46. Kepp O., Galluzzi L., Lipinski M., Yuan J., Kroemer G. Cell death assays for drug discovery. Nat. Rev. Drug Discov. 2011, 10:221-237.
47. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., Hullihen J., Pedersen P.L. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 2004, 324:269-275.
48. Ko Y.H., Verhoeven H.A., Lee M.J., Corbin D.J., Vogl T.J., Pedersen P.L. A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J. Bioenerg. Biomembr. 2012, 44:163-170.
49. Koobs D.H. Phosphate mediation of the Crabtree and Pasteur effects. Science 1972, 178:127-133.
50. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
51. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
52. Lampidis T.J., Bernal S.D., Summerhayes I.C., Chen L.B. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res. 1983, 43:716-720.
53. Le S.B., Hailer M.K., Buhrow S., Wang Q., Flatten K., Pediaditakis P., Bible K.C., Lewis L.D., Sausville E.A., Pang Y.P., Ames M.M., Lemasters J.J., Holmuhamedov E.L., Kaufmann S.H. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J. Biol. Chem. 2007, 282:8860-8872.
54. Lemarie A., Grimm S. Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer?. Oncogene 2011, 30:3985-4003.
55. Lessene G., Czabotar P.E., Colman P. Bcl-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 2008, 7:989-1000.
56. Lewis W., Levine E.S., Griniuviene B., Tankersley K.O., Colacino J.M., Sommadossi J.P., Watanabe K.A., Perrino F.W. Fialuridine and its metabolites inhibit DNA polymerase-γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc. Nat. Acad. Sci. U. S. A. 1996, 93(3592-3597):1996.
57. Mathupala S.P., Ko Y.H., Pedersen P.L. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25:4777-4786.
58. Maxwell P.H. A common pathway for genetic events leading to pheochromocytoma. Cancer Cell 2005, 8:91-93.
59. Miller W.H. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002, 7(Suppl. 1):14-19.
60. +). J. Biol. Chem. 1997, 272:9605-9608.
61. Modica-Napolitano J.S., Aprille J.R. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res. 1997, 47:4361-4365.
62. Modica-Napolitano J.S., Aprille J.R. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv. Drug Deliv. Rev. 2001, 49:63-70.
63. Moreira P.I., Custódio J., Moreno A., Oliveira C.R., Santos M.S. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J. Biol. Chem. 2006, 281:10143-10152.
64. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
65. Murphy M.P., Smith R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 2007, 47:629-656.
66. Neuzil J., Weber T., Gellert N., Weber C. Selective cancer cell killing by α-tocopheryl succinate. Br. J. Cancer 2001, 84:87-89.
67. Neuzil J., Weber T., Schröder A., Lu M., Ostermann G., Gellert N., Mayne G.C., Olejnicka B., Nègre-Salvayre A., Sticha M., Coffey R.J., Weber C. Induction of apoptosis in cancer cells by α-tocopheryl succinate: molecular pathways and structural requirements. FASEB J. 2001, 15:403-415.
68. Neuzil J., Dong L.F., Ramanathapuram L., Hahn T., Chladova M., Wang X.F., Zobalova R., Prochazka L., Gold M., Freeman R.E., Turanek J., Akporiaye E.T., Dyason J., Ralph S.J. Vitamin E analogues: a novel group of mitocans, anti-cancer agents that act by targeting mitochondria. Mol. Aspects Med. 2007, 28:607-645.
69. L-mediated apoptosis resistance. Mol. Cancer Ther. 2005, 4:23-31.
70. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
71. Pedersen P.L. Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment's roles together with hexokinase-2 in the "Warburg effect" in cancer. J. Bioenerg. Biomembr. 2008, 40:123-126.
72. Pedersen P.L. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. J. Bioenerg. Biomembr. 2012, 44:1-6.
73. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J., Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 2003, 278:37832-37839.
74. Pereira da Silva A.P., El-Bacha T., Kyaw N., dos Santos R.S., da-Silva W.S., Almeida F.C., Da Poian A.T., Galina A. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem. J. 2009, 417:717-726.
75. Prochazka L., Dong L.F., Valis K., Freeman R., Ralph S.J., Turanek J., Neuzil J. α-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channel. Apoptosis 2010, 15:782-794.
76. Ralph S.J., Neuzil J. Mitochondria as targets for cancer therapy. Mol. Nutr. Food Res. 2009, 53:9-28.
77. Ralph S.J., Rodríguez-Enríquez S., Neuzil J., Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol. Aspects Med. 2010, 31:29-59.
78. Ralph S.J., Rodríguez-Enríquez S., Neuzil J., Saavedra E., Moreno-Sánchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation-why mitochondria are targets for cancer therapy. Mol. Aspects Med. 2010, 31:145-170.
79. Ralph S.J., Moreno-Sanchez R., Neuzil J., Rodriguez-Enriquez S. Inhibitors of the succinate:quinine reductase/complex II regulate production of mitochondrial reactive oxygen species and protect normal cells from ischemic damage but induce specific cancer cell death. Pharm. Res. 2011, 28:2695-2730.
80. Roberts A.W., Seymour J.F., Brown J.R., Wierda W.G., Kipps T.J., Khaw S.L., Carney D.A., He S.Z., Huang D.C., Xiong H., Cui Y., Busman T.A., McKeegan E.M., Krivoshik A.P., Enschede S.H., Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 2012, 30:488-496.
81. Rodríguez-Enríquez S., Hernández-Esquivel L., Marín-Hernández A., Dong L.F., Akporiaye E.T., Neuzil J., Ralph S.J., Moreno-Sánchez R. Molecular mechanism of the selective effect of vitamin E analogues on cancer cell mitochondrial function. Biochim. Biophys. Acta 2012, 1817:1597-1607.
82. Rohlena J., Dong L.F., Kluckova K., Zobalova R., Goodwin J., Tilly D., Stursa J., Pecinova A., Philimonenko A., Hozak P., Banerjee J., Ledvina M., Sen C.K., Houstek J., Coster M.J., Neuzil J. Mitochondrially targeted α-tocopheryl succinate is antiangiogenic: potential benefit against tumor angiogenesis but caution against wound healing. Antioxid. Redox Signal. 2011, 15:2923-2935.
83. Saraste M. Oxidative phosphorylation at the fin de siècle. Science 1999, 283:1488-1493.
84. Sasaki R., Suzuki Y., Yonezawa Y., Ota Y., Okamoto Y., Demizu Y., Huang P., Yoshida H., Sugimura K., Mizushina Y. DNA polymerase gamma inhibition by vitamin K3 induces mitochondria-mediated cytotoxicity in human cancer cells. Cancer Sci. 2008, 99:1040-1048.
85. Sassi N., Biasutto L., Mattarei A., Carraro M., Giorgio V., Citta A., Bernardi P., Garbisa S., Szabò I., Paradisi C., Zoratti M. Cytotoxicity of a mitochondriotropic quercetin derivative: Mechanisms. Biochim. Biophys. Acta 2012, 817:1095-1106.
86. Scheffler I. Mitochondria 2008, John Wiley & Sons, Inc., Hoboken, New Jersey, USA. Second Edition.
87. Schiavi F., Boedeker C.C., Bausch B., Peçzkowska M., Gomez C.F., Strassburg T., Pawlu C., Buchta M., Salzmann M., Hoffmann M.M., Berlis A., Brink I., Cybulla M., Muresan M., Walter M.A., Forrer F., Välimäki M., Kawecki A., Szutkowski Z., Schipper J., Walz M.K., Pigny P., Bauters C., Willet-Brozick J.E., Baysal B.E., Januszewicz A., Eng C., Opocher G., Neumann H.P. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005, 294:2057-2063.
88. Shiau C.W., Huang J.W., Wang D.S., Weng J.R., Yang C.C., Lin C.H., Li C., Chen C.S. α-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. J. Biol. Chem. 2006, 281:11819-11825.
89. Shoshan M.C. 3-Bromopyruvate: targets and outcomes. J. Bioenerg. Biomembr. 2012, 44:7-15.
90. Shoshan-Barmatz V., Ben-Hail D. VDAC, a multi-functional mitochondrial protein as a pharmacological target. Mitochondrion 2012, 12:24-34.
91. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
92. Simard, E.P., Ward, E.M., Siegel, R., Jemal, A., in press. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J. Clin.
93. Simons A.L., Ahmad I.M., Mattson D.M., Dornfeld K.J., Spitz D.R. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007, 67:3364-3370.
94. Smith R.A., Hartley R.C., Murphy M.P. Mitochondria-targeted small molecule therapeutics and probes. Antioxid. Redox Signal. 2011, 15:3021-3038.
95. Suen D.F., Norris K.L., Youle R.J. Mitochondrial dynamics and apoptosis. Genes Dev. 2008, 22:1577-1590.
96. Sun F., Huo X., Zhai Y., Wang A., Xu J., Su D., Bartlam M., Rao Z. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell 2005, 121:1043-1057.
97. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51:794-798.
98. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., Chiao P.J., Achanta G., Arlinghaus R.B., Liu J., Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 2006, 10:241-252.
99. Trachootham D., Zhang H., Zhang W., Feng L., Du M., Zhou Y., Chen Z., Pelicano H., Plunkett W., Wierda W.G., Keating M.J., Huang P. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 2008, 112:1912-1922.
100. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
101. Truksa, J., Dong, L.F., Stursa, J., Rohlena, J., Goodwin, J., Stapelberg, M., Nguyen, M., Vondrusova, M., Kluckova, K., Zoratti, M., Ralph, S.J., Neuzil, J., submitted for publication. Mitochondrially targeted vitamin E succinate modulates the mitochondrial DNA transcripts: the role of complex II. Cell Res.
102. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., Roberts L., Tahir S.K., Xiao Y., Yang X., Zhang H., Fesik S., Rosenberg S.H., Elmore S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
103. Tzung S.P., Kim K.M., Basanez G., Giedt C.D., Simon J., Zimmerberg J., Zhang K.Y., Hockenbery D.M. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell Biol. 2001, 3:183-191.
104. +), a parkinsonism-causing toxin. Eur. J. Biochem. 2000, 267:200-206.
105. Valis K., Prochazka L., Boura E., Chladova M., Obsil T., Rohlena J., Truksa J., Dong L.F., Ralph S.J., Neuzil J. Hippo/Mst1 stimulates transcription of NOXA in a FoxO1-dependent manner. Cancer Res. 2011, 71:946-954.
106. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
107. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
108. Wallace D.C., Fan W., Procaccio V. Mitochondrial energetics and therapeutics. Annu. Rev. Pathol. 2010, 5:297-348.
109. Wang F., Ogasawara M.A., Huang P. Small mitochondria-targeting molecules as anti-cancer agents. Mol. Aspects Med. 2010, 31:75-92.
110. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
111. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21:297-308.
112. Weber T., Lu M., Andera L., Lahm H., Gellert N., Fariss M.W., Korinek V., Sattler W., Ucker D.S., Terman A., Schröder A., Erl W., Brunk U., Coffey R.J., Weber C., Neuzil J. Vitamin E succinate is a potent novel anti-neoplastic agent with high tumor selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo2L) in vivo. Clin. Cancer Res. 2002, 8:863-869.
113. Weber T., Dalen H., Andera L., Nègre-Salvayre A., Augé N., Sticha M., Loret A., Terman A., Witting P.K., Higuchi M., Plasilova M., Zivny J., Gellert N., Weber C., Neuzil J. Mitochondria play a central role in apoptosis induced by α-tocopheryl succinate, an agent with anticancer activity. Comparison with receptor-mediated pro-apoptotic signaling. Biochemistry 2003, 42:4277-4291.
114. Wilson W.H., O'Connor O.A., Czuczman M.S., LaCasce A.S., Gerecitano J.F., Leonard J.P., Tulpule A., Dunleavy K., Xiong H., Chiu Y.L., Cui Y., Busman T., Elmore S.W., Rosenberg S.H., Krivoshik A.P., Enschede S.H., Humerickhouse R.A. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2011, 11:1149-1159.
115. Xu K., Thornalley P.J. Involvement of glutathione metabolism in the cytotoxicity of the phenethyl isothiocyanate and its cysteine conjugate to human leukaemia cells in vitro. Biochem. Pharmacol. 2001, 61:165-177.
116. Youle R.J., Strasser A. The Bcl-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
117. Zeitlin B.D., Zeitlin I.J., Nör J.E. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J. Clin. Oncol. 2008, 26:4180-4188.
118. Zhivotovsky B., Galluzzi L., Kepp O., Kroemer G. Adenine nucleotide translocase: a component of the phylogenetically conserved cell death machinery. Cell Death Differ. 2009, 16:1419-1425.